clinical trial · NCT07007806
Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir
Healthy Volunteer StudyTreatment A-Bemnifosbuvir/Ruzasvir FDC administered fastingTreatment B-Omeprazole 20 mg dose administered fastingTreatment C-Bemnifosbuvir/Ruzasvir FDC administered simultaneously with 20 mg dose of Omeprazole fastingTreatment D-Bemnifosbuvir/Ruzasvir FDC administered 0.5 hour prior to 20 mg dose of OmeprazoleTreatment E-Omeprazole 40 mg administered fastingTreatment F-Bemnifosbuvir/Ruzasvir FDC administered 2 hours after 40 mg dose Omeprazole
brief summary
Drug-drug interaction study between Omeprazole and Bemnifosbuvir/Ruzasvir (BEM/RZR)
started
May 9, 2025
primary completion
Jun 28, 2025
completion
Jun 28, 2025
last updated
Aug 29, 2025
official title
A Phase 1, Open-Label, Single-Sequence Study to Assess the Effect of Multiple Doses of Omeprazole on the Single-Dose Pharmacokinetics of Bemnifosbuvir/Ruzasvir Fixed-Dose Combination in Healthy Adult Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol